Medical weight management | New York
Wegovy injection contains semaglutide and is taken once weekly. Its approved uses include weight management, cardiovascular risk reduction in qualifying adults, and treatment of qualifying noncirrhotic MASH. The injection, higher-dose presentation, and tablet have different indication and dose details.
Semaglutide activates GLP-1 receptors to affect appetite and glucose regulation. Wegovy does not contain tirzepatide. A higher-dose presentation is not a starting dose or a reason to increase treatment without review.
For weight management, Wegovy injection is approved for adults with obesity, selected adults with overweight and a weight-related condition, and children 12 years and older with obesity. Cardiovascular and MASH indications apply to specified adults. Pediatric treatment needs age-appropriate care.
Review the indication, risks, previous medicines, and ability to continue treatment. Start and increase the exact formulation under the prescriber’s plan. Learn injection use and storage for the device dispensed. Add nutrition support and agree on follow-up, side-effect reporting, and refills.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. For weight or cardiovascular risk treatment, discontinue when pregnancy is recognized and plan at least a two-month interval before pregnancy. The MASH label has separate benefit-risk language that needs specialist review.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Wegovy injection contains semaglutide and is taken once weekly. Its approved uses include weight management, cardiovascular risk reduction in qualifying adults, and treatment of qualifying noncirrhotic MASH. The injection, higher-dose presentation, and tablet have different indication and dose details. Semaglutide activates GLP-1 receptors to affect appetite and glucose regulation. Wegovy does not contain tirzepatide. A higher-dose presentation is not a starting dose or a reason to increase treatment without review.
For weight management, Wegovy injection is approved for adults with obesity, selected adults with overweight and a weight-related condition, and children 12 years and older with obesity. Cardiovascular and MASH indications apply to specified adults. Pediatric treatment needs age-appropriate care.
Wegovy HD is a higher-dose injectable presentation listed in the current label. It is not a starting dose and is not appropriate for every indication or age group. The clinician must review the exact indication, prior dose, tolerability, and label before considering it.
Wegovy injection contains semaglutide and is taken once weekly. Its approved uses include weight management, cardiovascular risk reduction in qualifying adults, and treatment of qualifying noncirrhotic MASH. The injection, higher-dose presentation, and tablet have different indication and dose details. For weight management, Wegovy injection is approved for adults with obesity, selected adults with overweight and a weight-related condition, and children 12 years and older with obesity. Cardiovascular and MASH indications apply to specified adults. Pediatric treatment needs age-appropriate care.
The Wegovy injection has a US chronic-weight-management indication for qualifying adolescents age 12 and older with obesity. Wegovy tablets have adult indications, so the same age rule cannot be applied to every formulation. A pediatric assessment reviews growth, health, family support and product-specific safety; a clinic listing does not establish pediatric prescribing availability.
Do not combine or overlap GLP-1 medicines or brands yourself. Product labels do not recommend this combination. The prescriber should review the exact current treatment and write any switch plan.
Both contain semaglutide, but the tablet and injection have different doses, administration, and indications. Tablets have adult weight and qualifying cardiovascular uses. Injection also has specified pediatric obesity and MASH uses. They are not milligram-for-milligram substitutes.
They contain the same active ingredient, semaglutide, but are separate products with different approved uses, doses and instructions. Wegovy has weight-management formulations and qualifying cardiovascular indications. Its injection also has a specified MASH indication. Ozempic injection is used for adult type 2 diabetes and qualifying cardiovascular and kidney risk reduction. Ozempic tablets are a separate oral diabetes product. Do not substitute brands, convert tablet milligrams to injection milligrams or take both together without a prescriber’s plan.
Wegovy is a Novo Nordisk medicine. Check the exact FDA-approved product, formulation and dispensing pharmacy. A product advertised as compounded semaglutide is not branded Wegovy.
Wegovy injection is given once weekly under the skin of the abdomen, thigh or upper arm. Rotate the site with each dose. Do not inject into a vein or muscle. Check the prescribed strength and follow the Instructions for Use for your exact device. A single-dose pen or syringe is discarded after use. The FlexTouch pen contains four weekly doses and needs a new needle for each injection. Do not share a FlexTouch pen. Ask the clinician or pharmacist to demonstrate it before the first dose or when the device changes. Wegovy tablets are swallowed, never injected.
Arrange a medical evaluation to review the intended use, weight and health history, current medicines, previous treatment, pregnancy plans and contraindications. The prescriber chooses whether an approved Wegovy formulation is suitable and plans dose escalation and follow-up. Bring your insurance information if coverage is being checked. Confirm the prescription and dispensing route with the treating team and pharmacy. An appointment does not guarantee a prescription or stock.
For someone starting Wegovy injection, the labeled starting dose is 0.25 mg once weekly for four weeks, followed by staged increases. Starting at 1.7 mg skips those stages and can increase gastrointestinal problems. The 1.7 mg dose can be a maintenance option for certain labeled uses, but that does not make it a routine starting dose. A switch from another formulation or a restart after missed treatment needs the prescriber’s specific instructions. Do not use a higher dose because it is the only strength available.
The storage rules depend on the product. Keep unused single-dose injection pens or syringes refrigerated at 2–8°C (36–46°F). Before cap removal, they may be kept at 8–30°C (46–86°F) for up to 28 days under the label’s instructions. FlexTouch pens are refrigerated before first use. After first use, its patient instructions allow up to 56 days refrigerated or at 20–25°C (68–77°F). Keep the pen capped, with the needle removed. Do not freeze any injection or use one that has frozen. Wegovy tablets stay in their original bottle at room temperature, protected from moisture. Follow the exact package instructions and ask the pharmacist about uncertain temperature exposure.
The clinician should identify the exact indication, age, weight and cardiovascular history, liver diagnosis when relevant, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and device readiness.
The injection starts at 0.25 mg once weekly and uses staged escalation. Adult weight maintenance is usually 1.7 mg or 2.4 mg weekly. The current label allows 7.2 mg weekly for certain adults after at least four weeks at 2.4 mg when additional weight reduction is clinically indicated. Other indications have specific maintenance instructions.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, and injection technique. MASH care requires liver-specific monitoring and coordination.
The clinician should identify the exact indication, age, weight and cardiovascular history, liver diagnosis when relevant, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and device readiness.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy history, heart rate, hypersensitivity, and injection technique. MASH care requires liver-specific monitoring and coordination.
Before starting or changing Wegovy, your clinician reviews the exact formulation and dose, age eligibility, injection technique, costs, safety concerns and follow-up. Liver-disease treatment may also require specialist coordination.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
Bronx
932 E 174th St, Bronx, NY 10460
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
37-15 23rd Ave, Astoria, NY 11105
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Bronx
2063A Bartow Ave, Bronx, NY 10475
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
30-07 36th Ave, Astoria, NY 11106
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Long Island
135 Mineola Blvd, Mineola, NY 11501
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Manhattan
259 1st Ave, New York, NY 10003
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Explore Nao Medical's broader weight-management program and treatment options.
Review the adult tablet pathway and its fasting administration rules.
Review Wegovy's liver indication, diagnosis, and specialist-coordination questions.
Compare tirzepatide using its own label and safety information.
Review a different oral GLP-1 product and interaction profile.
Content was updated August 2, 2026 from the sources cited here. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.